ABSTRACT
2,4-Dichlorophenol (2,4-DCP) is considered a priority pollutant due to its high toxicity. Therefore, it is urgent to develop technologies for the disposal of this pollutant. Various remediation processes have been proposed for the elimination of 2,4-DCP in contaminated water, however, most of them involve high costs of operation and maintenance. This study aimed to determine the capacity of remediation of 2,4-DCP in water by Typha latifolia L. wild plants. For that, the tolerance, removal, accumulation and biotransformation of 2,4-DCP by T. latifolia were investigated. The plants were exposed to 2,4-DCP solutions with a concentration range from 1.5 to 300 mgL-1 for 10 days. They exhibited a reduction in chlorophyll levels and growth rate when 2,4-DCP solutions were ≥30 mgL-1 and ≥50 mgL-1, respectively. The removal of contaminant was dose-depended, being 99.7% at 1.5-3 mgL-1, 59-70% at 10-70 mgL-1 and 35-42% at 100-300 mgL-1 of 2,4-DCP in the solution. Studies indicated that 2,4-DCP was mainly accumulated in root tissue rather than in shoot tissue. Acid hydrolysis of biomass extracts suggests 2,4-DCP bioconjugates formation in root tissue as a response mechanism. Additionally, an increment in glutathione S-transferase (GST) activity could indicate a 2,4-DCP conjugation with glutathione as a detoxification mechanism of T. latifolia.
Subject(s)
Biodegradation, Environmental/drug effects , Biotransformation/drug effects , Chlorophenols/toxicity , Drug Tolerance , Environmental Restoration and Remediation/methods , Plant Roots/metabolism , Typhaceae/metabolism , Anthelmintics/isolation & purification , Anthelmintics/toxicity , Chlorophenols/isolation & purification , Glutathione Transferase/metabolism , Water Pollutants, ChemicalABSTRACT
We presents the case of a patient, 12-year-old, asthmatic, diagnosed by means of polysomnography of obstructive sleep apnea syndrome (OSAS). Improvement take place after tonsillectomy. This case provide evidence for the condition in childhood, headache being the sole annoyance noticed and surgery seems successful.
Subject(s)
Sleep Apnea, Obstructive/etiology , Tonsillectomy , Tonsillitis/complications , Tonsillitis/surgery , Child , Humans , MaleSubject(s)
Lung Diseases/diagnostic imaging , Sarcoidosis/diagnostic imaging , Adult , Anti-Inflammatory Agents/therapeutic use , Bronchoscopy , Humans , Lung Diseases/drug therapy , Male , Methylprednisolone/therapeutic use , Radiography, Thoracic , Sarcoidosis/drug therapy , Tomography, X-Ray ComputedABSTRACT
The present study proved that desmopressin (DDAVP) (1 microgram DDAVP/12 h/5 días) does not affect ovary, testis and adrenal development in immature Wistar rats (17 days old), because the DDAVP does not modify the weight of the aforementioned organs as compared with the control group. Nevertheless, the male adults Wistar rats (80 days old) showed lower serum testosterone concentrations than the control group, after injection of 4 micrograms/day (2 micrograms/12 h) or 8 micrograms/day (4 micrograms/12 h) of DDAVP during a 5 days period time. Moreover, paradoxical significant lower concentrations of serum testosterone were found in 4 micrograms DDAVP/day-treated rats than in 8 micrograms DDAVP/day-treated ones. The former also showed a decreased number of spermatozoa as compared with the latter and with the control group. The percentage of mobile spermatozoa was lower in rats treated with both concentrations of DDAVP as compared with the control group. Therefore, desmopressin does not delay gonadal and adrenal growth in immature rats, but, at low doses, it affects the testicular function and the mobility of the spermatozoa in male adult rats.
